<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004382</url>
  </required_header>
  <id_info>
    <org_study_id>199/12022</org_study_id>
    <secondary_id>RUH-0330795B</secondary_id>
    <nct_id>NCT00004382</nct_id>
  </id_info>
  <brief_title>Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Compare the effectiveness of a single dose of tin mesoporphyrin and special
      blue light phototherapy in controlling hyperbilirubinemia in premature newborns in Greece.

      II. Evaluate the dose of tin mesoporphyrin sufficient to alleviate the need for phototherapy
      without adverse effects in these newborns.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients are randomly assigned to a clinical group within 96 hours of
      birth. Patients are stratified by gestational age, clinical status, and age at treatment.

      One group receives tin mesoporphyrin. Patients are crossed to phototherapy if the plasma
      bilirubin concentration reaches the treatment threshold.

      The second group receives phototherapy with Special Blue fluorescent lamps for at least 24
      hours. Patients receive a second phototherapy course if the plasma bilirubin concentration
      reaches the treatment threshold within 24 hours of the first course.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>80</enrollment>
  <condition>Hyperbilirubinemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tin mesoporphyrin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phototherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Premature infants of gestational age 210 to 251 days

          -  No blood group isoimmunization (direct Coombs' positive), e.g., rhesus or ABO

          -  No glucose-6-phosphate dehydrogenase deficiency

        --Prior/Concurrent Therapy--

          -  No maternal phenobarbital in last month of pregnancy

        --Patient Characteristics--

        Renal: No congenital renal abnormality

        Cardiovascular: No congenital heart abnormality

        Pulmonary: No asphyxia requiring assisted ventilation at delivery

        Other: No other major congenital abnormality, i.e.:

          -  Central nervous system

          -  Chromosomal

          -  Gastrointestinal

        No evident or suspected congenital infection, i.e.:

          -  Cytomegalovirus

          -  Herpes

          -  Rubella

          -  Syphilis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Attallah Kappas</last_name>
    <role>Study Chair</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>September 8, 2008</last_update_submitted>
  <last_update_submitted_qc>September 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2008</last_update_posted>
  <keyword>hematologic disorders</keyword>
  <keyword>hyperbilirubinemia</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tin mesoporphyrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

